FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to therapy and endocrinology, and concerns hypertension treatments in women in combination with hormone replacement therapy. That is ensured by introduction of Drospirenone (DRSP) in amount 0.5-3 mg/day and 17β-estradiol in amount 1-3 mg/day.
EFFECT: invention provides maximally effective arterial pressure reduction with minimum by-effects in given category of patients.
17 cl, 3 ex, 1 tbl, 8 dwg
Authors
Dates
2009-11-27—Published
2003-03-24—Filed